– By Dilip Davda
- The company is engaged in providing crop solutions with agrochemicals and seeds being prime offerings.
- It marked steady growth in its top and bottom lines for the reported periods.
- Based on its recent average financial data, the issue appears aggressively priced.
- Well-informed investors may park funds for medium to long term.
ABOUT COMPANY:
Crystal Crop Protection Ltd. (CCPL) is a crop solutions company with agrochemicals and seeds at the core of its offerings. Its diversified portfolio includes (i) products for crop protection such as herbicides, fungicides, insecticides and natural crop solutions such as bio-stimulants, bio-protectants, plant growth regulators, liquid fertilizers and micro nutrients; and (ii) seeds such as for field crops, vegetable crops and flowers.
CCPL’s offerings are customized for Indian farmers through research and development (“R&D”) including collaborations with various multinational companies, delivering relevant solutions that aim to enhance farm economics, yield, productivity and profitability. The company operates on a fully integrated model, that integrates robust synthesis R&D in crop protection products and natural crop solutions as well as robust seeds breeding program, with backward-integrated technology enabled manufacturing and pan-India distribution, with a farmer-centric approach.
It has dedicated and strategic focus on R&D, which it considers integral to its ability to offer quality crop protection products and natural crop solutions and seeds for various crops. Its R&D teams focus on (i) developing novel formulations, based on its analysis of existing gaps in the industry and prevailing needs of customers; and (ii) extensive breeding programs, leading to creation of renowned brands for its business verticals. Its robust seeds breeding programs, anchored by an extensive germplasm bank, using conventional and modern tools, deliver seeds which are locally adapted, high yielding, stress tolerant hybrids and varieties. Over the years, it has established as a progressive force in the Indian seed industry, actively engaging in strategic collaborations and technology partnerships to drive innovation and sustainable growth. (Source: F&S Report)
It has signed several key agreements aimed at enhancing crop performance, farmer profitability and industry advancement. (Source: F&S Report). The company offers a range of product sizes, including ‘farmer friendly packs’ for smallholder farmers and large pack sizes for progressive farmers. As of June 30, 2026, its crop protection products are sold under its corporate brands namely “CRYSTAL” and “Saffire”, to its consumers with over 193 product brands. CCPL’s crop protection branded businesses have delivered a strong growth of 46.08% from Fiscal 2024 to Fiscal 2026, significantly outperforming the industry average of 10–13% over the same period. (Source: F&S report). It also offers crop protection products and natural crop solutions internationally which focuses on the export of its branded formulations and Technicals, primarily to Bangladesh, Nepal, Tanzania, Uganda, Ethiopia, Jordan, Turkmenistan, Bhutan, Armenia and Indonesia. As of June 30, 2026, it had 14717 active distributors on PAN India basis. It has applied for 28 patents out of which 18 patents are approved.
In relation to its seeds business, the company operates three seed processing units. Two seed processing units are at Hyderabad, Telangana (“Hyderabad Seed Units”) and one seed processing unit is at Bengaluru, Karnataka (“Bengaluru Seed Unit”) which dries, grades, treats and packs seeds for field crops, vegetables and flower seeds. As of June 30, 2026, the Hyderabad Seed Units and the Bengaluru Seed Unit have an installed capacity of 48,213.79 MT and 1,722.00 MT respectively. As of June 30, 2026, it has obtained registrations for 139 Technicals, 601 Formulations, 147 Technicals/Formulations, and 45 Technicals under Section 9 (3) of the Insecticides Act, 1968.As of the said date, it had 2117 employees on its payroll, and additional 1748 third party individuals.
ISSUE DETAILS/CAPITAL HISTORY:
The company is coming out with its maiden book building route comobo IPO of 16754275 equity shares worth Rs. 455.72 cr. at the upper cap. The IPO consists of fresh equity shares worth Rs. 355.00 cr. (approx. 13051581 equity shares at the upper cap), and the Offer for Sale (OFS) of 3702694 equity shares (worth Rs. xx cr. at the upper cap). The company has announced a price band of Rs. 259.00– Rs. 272.00 per equity shares of Rs. 10 each. The issue opens for subscription on November 18, 2026, and will close on November 20, 2026. The minimum application to be made is for 55 shares and in multiples thereon, thereafter. Post allotment, shares will be listed on BSE and NSE. The issue constitutes 10.27% of the post-IPO paid-up equity capital. From the net proceeds of fresh equity issue, the company will utilize Rs. 247.94 cr. for repayment/prepayment of certain borrowings, Rs. 22.06 cr. for investment in its material subsidiary Saffire Crop Science Pvt. Ltd., towards repayment/prepayment of certain borrowings, and the rest for general corporate purposes.
The company has reserved 91912 equity shares (worth Rs. 2.50 cr. at the upper cap) for its eligible employees, and offering them a discount of Rs. 25 per share. From the rest, it has allocated not more than 50% for QIBs, not less than 15% for HNIs, and not less than 35% for Retail investors.
The joint Book Running Lead Managers (BRLMs) to this issue are IIFL Capital Services Ltd., DAM Capital Advisors Ltd., and Motilal Oswal Investment Advisors Ltd., while MUFG Intime India Pvt. Ltd. is the registrar to the issue.
Having issued/converted initial equity shares at par value, the company has issued further equity shares in the price range of Rs. 240.99 – Rs.1741.70 per share (based on Rs. 10 FV), between December 2011, and October 2026. It has also issued bonus shares in the ratio of 7 for 1 in August 2011, 15 for 1 in March 2014. The average cost of acquisition of shares by the promoters/selling stakeholders is Rs. NIL, Rs. 23.51, and Rs. 55.26 per share.
Post-IPO, its current paid-up equity capital of Rs. 150.12 cr. (150116700 equity shares) will stand enhanced to Rs. 163.17 cr. (163168281 equity shares). Based on the upper cap of the price band, the company is looking for a market cap of Rs. 4438.18 cr.
FINANCIAL PERFORMANCE:
On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted a total income/net profit, of Rs. 2271.71 cr. / Rs. 87.24 cr. (FY24), Rs. 2731.94 cr. / Rs. 118.39 cr. (FY25), and Rs. 3180.98 cr. / Rs. 144.91 cr. (FY26). For Q1 of FY27 ended on June 30, 2026, it earned a net profit of Rs. 135.78 cr. on a total income of Rs. 1209.21 cr. The company posted growth in its performances for the reported periods. Rising trade receivables year-on-year raise concern. Its contingent liabilities stood at Rs. 113.27 cr. as of June 30, 2026. According to the management, its trade receivables are in line with the general trends in the industry.
For the last three fiscals, the company has posted an average EPS of Rs. 10.01 (basic) and an average RoNW of 7.06 %. The issue is priced at a P/BV of 1.59 based on its NAV of Rs. 170.57 as of June 30, 2026, and at a P/BV of 1.62 based on its post-IPO NAV of Rs. 167.45 per share at the upper cap.
If we attribute FY27 annualized super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at P/E of 8.17. Based on FY26 earnings, the P/E stands at 30.63. Though issue appears lucratively priced on the basis of annualized super financial performance for FY27, it remains aggressively priced on the basis of its recent average financial data.
For the reported periods, the company has reported PAT Margins of 3.84% (FY24), 4.33% (FY25), 4.56% (FY26), 11.23% (Q1-FY27), and RoCE margins of 10.39%, 16.38%, 16.06%, 9.78%, respectively, for the referred periods.
DIVIDEND POLICY:
The company has paid a dividend of 7.40% (FY24), 6.70% (FY25), 10.70% (FY26). It has adopted an amended dividend policy in December 2025, based on its earnings and future prospects.
COMPARISON WITH LISTED PEERS:
As per the offer document, the company has shown Kaveri Seeds, Sumitomo Chemical, Bayer Crop, Rallis India, Dhanuka Agritech, as its listed peers. They are currently trading at a P/E of 14.6, 31.5, 20.8, 17.9, and 14.3 (as of November 13, 2026). However, they are not truly comparable on an apple-to-apple basis. This comparison appears to be an eyewash.
MERCHANT BANKER’S TRACK RECORD:
The three BRLMs associated with this issue have handled 115 public issues in the past three fiscals, out of which 30 issues closed below the offer price on listing date.
CONCLUSION:
CCPL is engaged in providing crop solutions with agrochemicals and seeds being prime offerings. The company is one of the leading companies is the segment, with major focus on R & D. It marked steady growth in its top and bottom lines for the reported periods. Based on its recent average financial data, the issue appears aggressively priced. It is operating in a highly competitive and fragmented segment. Well-informed investors may park funds for medium to long term.
Review By Dilip Davda on August, 2026
Review Author
DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. My reviews do not cover GMP market and operators game plans. Readers must consult a qualified financial advisor before making any actual investment decisions, based the on information published here. With entry barriers, SEBI wants only well-informed investors to participate in such offers. With crazy listings in the recent past, SME IPOs drew the attention of investors across the board and lead to seer madness. However, as SME issues have entry barriers and continued low preference from the broking community, any reader taking decisions based on any information published here does so entirely at their own risk. The above information is based on information available as of date coupled with market perceptions. The Author has no plans to invest in this offer.
About Dilip Davda
Dilip Davda is veteran journalist associated with stock market since 1978. He is contributing to print and electronic media on stock markets/insurance/finance since 1985.
Dilip Davda is a leading reviewer of public issues and NCDs in the primary stock market in India. The knowledge he gained over 3 decades while working in the stock market and a strong relationship with popular lead managers makes his reviews unique. His detailed fundamental and financial analysis of companies coming up with IPOs helps investors in the primary stock market. Dilip Davda has a special interest in analyzing the SME companies and writing reviews about their public issues. His reviews are regularly published online and in news papers.
(Dilip Davda -SEBI registered Research Analyst-Mumbai,
Registration no. INH000003127 (Perpetual)
Email id: dilip_davda@rediffmail.com ).
